Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically Relevant Questions

When:  Jun 5, 2016 from 6:00 PM to 8:30 PM (CT)

Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically Relevant Questions

Sunday, June 5, 2016
Sheraton Grand Chicago
Chicago, Illinois

Presented by prIME Oncology in collaboration with the Society for Immunotherapy of Cancer

This satellite symposium, which was held during the 2016 ASCO Annual Meeting, presented recent findings from clinical trials investigating immunotherapeutic agents in newly diagnosed non-small cell lung cancer (NSCLC). Attendees learned how to apply these findings to appropriately selected patients, monitor efficacy of immunotherapies, recognize adverse events and apply methods to mitigate toxicity. The symposium also discussed the rationale for, and research findings on, novel combinations that include immunotherapies and other agents.

Click here to learn more about this program!

Chair
Roy S. Herbst, MD, PhD – Yale Cancer Center

Session Speakers and Topics

6:00 – 6:30 p.m. Registration and Dinner
Welcome and Introduction

Roy S. Herbst, MD, PhD – Yale Cancer Center
6:30 – 6:45 p.m.


6:45 – 8:25 p.m.
Recent Progress in Immunotherapy for NSCLC
Roy S. Herbst, MD, PhD – Yale Cancer Center

Taking It to the Clinic: Questions and Considerations
All Faculty
  Question #1: Selection of Therapy in Advanced NSCLC
Ramaswamy Govindan, MDWashington University School of Medicine
Faculty Panel Discussion
  Question #2: Monitoring Response to Immunotherapy Treatment
Francesco Grossi, MD National Institute for Cancer Research
Faculty Panel Discussion
  Question #3: Managing Immune-Related Adverse Events
Leena Gandhi, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School
Faculty Panel Discussion
  Question #4: Immunotherapy Beyond Progression
Ramaswamy Govindan, MDWashington University School of Medicine
Faculty Panel Discussion
  Question #5: Combining Immunotherapies with Other Treatment Approaches
Francesco Grossi, MD National Institute for Cancer Research
Faculty Panel Discussion
8:25 – 8:30 p.m. Closing Remarks: prIME Points
Roy S. Herbst, MD, PhD – Yale Cancer Center

Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Other Information
This educational activity was supported by grants from Incyte and Merck and Co, Inc.

Not an official event of the 2016 ASCO Annual Meeting
Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation

Location

Sheraton Grand Chicago
Chicago, IL